These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35172589)

  • 1. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
    N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
    Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
    Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapies for the Treatment of Uveal Melanoma-History and Future.
    Schank TE; Hassel JC
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31344957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
    Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
    Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
    Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
    Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
    Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
    Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
    Klabusay M; Bábková B
    Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveal melanoma: In the era of new treatments.
    Wespiser M; Neidhardt E; Negrier S
    Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.
    Martinez-Perez D; Viñal D; Solares I; Espinosa E; Feliu J
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
    Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
    Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
    Damato BE; Dukes J; Goodall H; Carvajal RD
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
    Hua G; Carlson D; Starr JR
    J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.